6. What are potential problems of methotrexate medical management?
Correct answer: Treatment failure is the main worry with methotrexate therapy of an unruptured ectopic pregnancy. Every potential patient has a constellation of findings that factor into deciding whether it is safe to treat her medically. In general, the more advanced the gestation, the more likely it is to fail methotrexate and ultimately rupture without surgery. When evaluating a patient, at a minimum she must have an unruptured mass, be hemodynamically stable, and desire future fertility (see Chapter 5 for other relative and absolute indications and contraindications). Medical treatment is considered to have failed when the βhCG levels either increase or plateau by day 7 post-injection or when the tube ruptures. If medical therapy fails, rapid surgical intervention may be necessary. Patients treated with methotrexate must therefore be able to return for follow-up care.
Methotrexate side effects are usually very mild in the typical, young, otherwise healthy patient. On occasion, significant nausea, stomatitis, diarrhea, dizziness, or pneumonitis can occur. During therapy, women should discontinue folic acid supplements (eg, prenatal vitamins) and avoid non-steroidal anti-inflammatory drugs.
Treatment-related complications frequently include at least one episode of increased abdominal pain due to swelling of the tube. Typically it is a milder event than with tubal rupture, is of limited duration (1–2 days), and should not be associated with a surgical abdomen or hemodynamic instability. A sonogram can help confirm the absence of intra-abdominal blood.